Growth Factor News and Research

RSS

Chronic methamphetamine abuse linked to cardiovascular disease

The study is being published the week of June 25 in an advanced online edition of the Proceedings of the National Academy of Sciences.

26 Jun 2007

Basically eating fish may protect against type of blindness

Increasing intake of the omega-3 fatty acids DHA and EPA, found in popular fish-oil supplements, may protect against blindness resulting from abnormal blood vessel growth in the eye, according to a study published online by the journal Nature Medicine on June 24.

26 Jun 2007

Avastin helps those with radiation retinopathy

Patients with radiation retinopathy who were destined to go blind within five years now can keep their sight longer through localized treatment with Avastin, a well-known cancer drug, according to a two-year study published in the June, 2007 Archives of Ophthalmology.

23 Jun 2007

Autistic boys have high levels of growth hormones

Boys with autism and autism spectrum disorder had higher levels of hormones involved with growth in comparison to boys who do not have autism, reported researchers from the National Institutes of Health, the Centers for Disease Control and Prevention, the Cincinnati Children's Hospital and the University Of Cincinnati College Of Medicine.

22 Jun 2007

New target for therapies for retinopathy

A protein long thought to be one of the body's supporting players has quietly been taking a lead role in healthy eyesight, a discovery that could rapidly lead to treatments for babies born before their eyes are finished growing, University of Florida and Harvard Medical School researchers have found.

19 Jun 2007

Otosclerosis gene identified

A gene responsible for the single most common cause of hearing loss among white adults, otosclerosis, has been identified for the first time, a scientist told the annual conference of the European Society of Human Genetics in Nice, France.

19 Jun 2007

Injected neural stem cells reduce Parkinson's symptoms in primates

Primates with severe Parkinson's disease were able to walk, move, and eat better, and had diminished tremors after being injected with human neural stem cells, a research team from Yale, Harvard, the University of Colorado, and the Burnham Institute report in Proceedings of the National Academy of Sciences.

14 Jun 2007

Gamma-secretase acts as a tumor suppressor

Researchers at Burnham Institute for Medical Research (Burnham) have provided the first evidence that gamma-secretase, an enzyme key to the progression of Alzheimer's, acts as a tumor suppressor by altering the pathway of epidermal growth factor receptor (EGFR), a potential treatment target for cancer.

14 Jun 2007

New regulator of fat metabolism identified

Over the past several years, animal studies have shown that high-fat, low-carbohydrate “ketogenic” diets cause demonstrable changes in metabolism and subsequent weight loss.

8 Jun 2007

Angiogenesis gene polymorphisms predict tumor recurrence in stage II and III colon cancer

Researchers at the University of Southern California (USC) have identified specific molecular markers that may help to predict tumor recurrence in stage II and III colon cancer patients.

8 Jun 2007

Mouse hibernation hormones described

A key hormone enables starving mice to alter their metabolism and “hibernate” to conserve energy, revealing a novel molecular target for drugs to treat human obesity and metabolic disorders, UT Southwestern Medical Center researchers have found.

8 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Axitinib shows promise in treatment of advanced thyroid cancer

The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported at the annual meeting of the American Society for Clinical Oncology in Chicago.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Gene therapy delivery of nerve growth factors reverses erectile dysfunction in mice

Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine researchers.

5 Jun 2007

Scientists have captured on video the intracellular version of a postal delivery service

Reporting in the journal Biochemical and Biophysical Research Communications (BBRC), bioengineering researchers at UC San Diego published videos of a key message-carrying protein called paxillin moving abruptly from hubs of communication and transportation activity on the cell surface toward the nucleus.

3 Jun 2007

Blood test may help signal tumor's remission, return in throat cancer patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research .

3 Jun 2007

Exercise helps maintain muscle in elderly

Why do older people tend to lose muscle mass and grow frail?

1 Jun 2007

Growth factors and the environment combine to increase brain maturation

Recent studies by this group have demonstrated that rodents, brains are sensitive to the influences of the environment and in particular that maturation of the visual system is accelerated in an enriched environment, where animals can explore new objects, engage in physical exercise and play.

30 May 2007

Guidelines on skin reactions to Epidermal Growth Factor Receptor Inhibitors (EGFRIs)

Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."

24 May 2007